AI Fills The Decision-Making Gaps In Process Analytical Technology

By Devendra Ridhurkar, Ph.D.

The pharmaceutical industry has experienced significant transformation as manufacturers aim to improve product quality, accelerate development schedules, reduce operational costs, and strengthen supply chain robustness. Although conventional batch manufacturing has been beneficial to the industry for many years, its linear processes, extensive offline evaluations, lengthy production timelines, and delayed quality assessments may hinder manufacturing flexibility.¹^,²

An alternative that combines processes including material feeding, blending, granulation, drying, tableting, and coating into a cohesive production process is called continuous manufacturing (CM). It can increase process flexibility, shorten production times, and improve process control by facilitating continuous processing and real-time monitoring.¹^,³

However, a manufacturing system cannot be considered intelligent just by linking unit processes. Large amounts of data are produced by continuous operations using factory information platforms, automation systems, spectroscopic instruments, and process sensors. These data must be transformed by manufacturers into prompt, scientifically supported decisions. This is the point at which artificial intelligence (AI) and process analytical technology (PAT) complement one another.⁴^-⁶

While AI can recognize intricate correlations, forecast process behavior, spot abnormalities, and aid in decision-making, PAT offers real-time visibility into process and product properties. When combined, they offer a mechanism to move beyond reactive quality testing to proactive and anticipatory process management.⁵^-⁷

Why Continuous Manufacturing Needs Intelligence

Continuous manufacturing involves interconnected unit operations in which changes at one stage can affect downstream performance. For example, variations in feeder performance or raw material properties can influence  downstream steps all the way to finished-product quality. ¹^-³

Modern facilities can generate high-frequency measurements of temperature, pressure, flow, moisture, particle characteristics, vibration, and chemical composition. However, collecting data does not automatically provide process understanding. Traditional univariate monitoring may identify that a parameter has changed, but it may not reveal how several simultaneous changes interact or what their effect will be on product quality. ³^,⁵

Manufacturers therefore need analytical approaches capable of integrating multidimensional information and identifying emerging patterns. The objective should not be to introduce AI simply because it is technologically advanced. Instead, manufacturers should identify specific process or quality problems for which advanced analytics can provide measurable value.⁸^,⁹

PAT: The Foundation Of Intelligent Manufacturing

PAT provides the measurement infrastructure required for intelligent continuous manufacturing. The U.S. FDA introduced its PAT framework to encourage pharmaceutical manufacturers to design, analyze, and control processes using timely measurements of critical quality and performance attributes.⁴

In a continuous manufacturing environment, PAT acts as the process "sensory system." Online, inline, and at-line measurements provide information about the state of materials and processes while production is occurring. PAT implementation in continuous pharmaceutical processes has been demonstrated across blending, granulation, drying, roller compaction, compression, coating, and other unit operations.⁵^,⁶

Common PAT technologies include:

• near-infrared (NIR) spectroscopy for blend uniformity, moisture, and chemical concentration,
• Raman spectroscopy for chemical identification and composition,
• Fourier transform infrared (FTIR) spectroscopy for chemical monitoring,
• Particle size measurement for granulation and milling, and
• process sensors for temperature, pressure, flow, and equipment performance.⁵^,¹⁰^-¹²

PAT data become particularly powerful when combined with multivariate data analysis (MVDA). Techniques such as principal component analysis (PCA), partial least squares (PLS), and multivariate statistical process control can identify relationships among multiple process variables and detect abnormal process behavior.⁶^,¹³

However, PAT's true value lies in connecting measurements to process understanding and control. Real-time measurements can support process control and, where adequately justified, real-time release testing (RTRT).⁴^,⁶^,¹⁴

From PAT Data To AI-Driven Decisions

PAT provides information about what is happening in a process. AI can help determine why it is happening and what may happen next.

Machine learning (ML) models can learn relationships between process variables and quality outcomes from historical and real-time data. Artificial neural networks, support vector machines, decision trees, and other ML approaches have been investigated for pharmaceutical process monitoring, prediction, and optimization.⁸^,⁹

One important application is the development of soft sensors, or virtual sensors. Some quality attributes cannot be measured continuously or economically using physical analytical instruments. AI models can estimate these attributes using information from available PAT and process measurements. Recent pharmaceutical manufacturing reviews describe applications involving prediction of granule properties, moisture, quality attributes, and adaptive PAT frameworks.⁸^,⁹

AI can also support anomaly detection. Rather than relying only on predefined limits, algorithms can identify subtle changes in multidimensional process behavior. This can support earlier detection of feeder instability, sensor drift, unexpected spectral changes, equipment degradation, or process oscillations.⁸^,¹⁵

Predictive maintenance is an additional possibility. Because unplanned downtime can disrupt interrelated activities, continuous manufacturing relies on dependable equipment performance. AI can support maintenance planning by analyzing equipment and processing data to find trends linked to deterioration.⁹^,¹⁶

By assessing the connections between operational circumstances, process performance, quality attributes, yield, waste, and energy consumption, AI may help optimize processes even further. Nevertheless, optimization suggestions must stay within operational ranges that are suitably regulated and supported by science.⁹^,¹⁷

Integrating AI And PAT: From Monitoring To Adaptation

The relationship between PAT and AI can be summarized simply: PAT provides process visibility; AI provides process intelligence.

An integrated workflow can follow five stages.

1. Data acquisition: PAT instruments and process sensors continuously collect measurements from manufacturing operations.

2. Data integration: In a regulated data environment, data from PAT systems, manufacturing execution systems (MES), distributed control systems (DCS), laboratory information management systems (LIMS), and other relevant platforms are combined. Instead of seeing individual systems as separate data sources, smart manufacturing frameworks highlight the significance of combining operational and information technology.¹⁶^,¹⁸

3. AI analytics: Analytical models that have been validated find trends, forecast quality characteristics, spot irregularities, and assess the effectiveness of machinery or processes.⁸^,⁹

4. Decision support: In order to modify feeder configurations, drying conditions, granulation parameters, or compression conditions, the system makes recommendations to operators or control systems.

5. Process control: While PAT verifies whether the process returns to the intended state, authorized control methods can make modifications when necessary and validated.⁶^,¹⁹

Manufacturing can transition from basic monitoring to predictive and adaptive control using this path. Research on integrated continuous pharmaceutical technologies shows how sophisticated control, PAT, and linked processes can function as a production system instead of separate technologies.¹⁹

Practical Applications And Industry Lessons

There are numerous practical applications for the combination of PAT, sophisticated analytics, and continuous processing.

Spectroscopic measurements can give real-time information regarding blend composition and homogeneity in continuous blending. In order to detect emerging variability and facilitate remedial action, sophisticated models can integrate these measures with feeder and process data.⁵^,⁸

Granule formation in continuous granulation can be understood by combining measures of moisture, particle size, and process torque. ML models have been studied for enhanced process control and granule property prediction.⁸^,⁹

Compression force, feeder performance, material characteristics, and PAT measurements are examples of process data that might help forecast tablet quality aspects. Additionally, real-time quality assessment and release techniques have been studied using NIR-based methods.¹⁴^,²⁰

PAT-enabled platforms in continuous direct compression show how real-time measurements may be integrated into process comprehension and control instead of being used only for post-process analysis.²¹

The more general takeaway is that AI should be used in situations when it resolves specific manufacturing issues. If a simpler statistical model effectively solves the issue or if the underlying measuring system is faulty, a complicated algorithm offers minimal benefit. Recent reviews also identify limited data, model interpretability, extrapolation, uncertainty, and integration with existing workflows as important barriers to broader ML adoption.⁹^,²²

Implementation And Regulatory Considerations

Successful AI–PAT implementation begins with the data foundation. Manufacturers should assess data quality, instrument reliability, system integration, data integrity, and cybersecurity before developing complex AI models. Industry 4.0 research in pharmaceutical manufacturing emphasizes that digital transformation requires coordinated technological, regulatory, and organizational capabilities.¹⁶^,¹⁸

Organizations should begin with high-value, manageable use cases rather than attempting to automate an entire manufacturing facility at once. Predictive maintenance, anomaly detection, or a specific PAT-based quality prediction may provide appropriate starting points.⁹

AI models used in regulated manufacturing require appropriate validation, documentation, change control, and life cycle management. Organizations should define model inputs, intended use, performance criteria, limitations, monitoring requirements, and procedures for handling model drift or retraining. FDA has specifically identified AI in drug manufacturing as an emerging area requiring consideration of model development, performance, data, and life cycle management.²³

Regulatory principles established through FDA PAT guidance and ICH guidelines — including ICH Q8(R2), Q9(R1), Q10, Q13, Q2(R2), and Q14 — provide a foundation for process understanding, risk management, pharmaceutical quality systems, analytical procedure development, and continuous manufacturing.⁴^,²⁴^-²⁸ ICH Q13 specifically addresses scientific and regulatory considerations for development, implementation, operation, and life cycle management of continuous manufacturing.²⁴

Human oversight also remains essential. AI should augment scientific and manufacturing expertise rather than replace it. Operators, process scientists, engineers, quality professionals, and data scientists must work together to establish scientifically justified applications and appropriate controls.²³^,²⁹

A Practical Road Map

Pharmaceutical organizations considering AI-enabled continuous manufacturing can adopt a phased approach:

• First, assess digital maturity. Evaluate PAT infrastructure, automation, data availability, system integration, and workforce capabilities.
• Second, establish data governance. Ensure that data are accurate, traceable, secure, and suitable for model development.
• Third, select a high-value use case. Prioritize applications with a clearly defined manufacturing problem and measurable benefit.
• Fourth, develop and validate the model. Compare AI performance with appropriate conventional analytical methods and establish predefined acceptance criteria.
• Fifth, integrate with process control. Begin with decision support and progress toward automated control only when the application is scientifically justified and appropriately validated.
• Finally, monitor performance throughout the life cycle. AI models should be periodically evaluated for performance degradation, data drift, and changes in the manufacturing process.

This phased approach aligns digital transformation with established quality and risk management principles rather than treating AI as a stand-alone technology initiative.¹⁶^,²⁹

Looking Ahead

The development of increasingly intelligent pharmaceutical manufacturing systems is anticipated to accelerate because of the convergence of AI and PAT. Manufacturers may be able to test control strategies and model process modifications using digital twins before putting them into practice on actual machinery. Recent research especially recognizes the integration of ML with digital twins as an important approach for advanced pharmaceutical manufacturing.⁹

When models impact quality-critical decisions, explainable AI may also become more crucial, especially when manufacturers need to comprehend model behavior, uncertainty, and constraints.²²^,²³

The long-term objective is not a factory with more sensors or algorithms. Verified control techniques, process understanding, predictive analytics, and reliable measurements all work together in this production environment.

Conclusion

Continuous manufacturing provides the operational foundation for pharmaceutical production, and PAT provides the real-time visibility needed to understand and manage that platform. AI may build on this foundation by transforming vast volumes of process data into anomaly detection, predictive insights, and decision assistance.¹^-⁶^,⁸

The biggest opportunity is to judiciously integrate AI where it offers significant gains in process knowledge, quality assurance, reliability, and operational efficiency rather than replacing traditional manufacturing methods with AI.

Organizations may gradually transition from monitoring to prediction and, when appropriate, adaptive control if they build solid data foundations, start with high-value use cases, properly verify AI applications, and retain human oversight.²³^,²⁹

In the end, AI offers an analytical layer for deciphering what those systems see, while PAT serves as continuous manufacturing's eyes and ears. Their integration can assist the pharmaceutical sector in transitioning to manufacturing systems that are more resilient, responsive, predictive, and able to maintain quality over the course of a product's life cycle.

References:

1. Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015;10(3):191-199. doi:10.1007/s12247-015-9215-8.
2. Vanhoorne V, Vervaet C. Recent progress in continuous manufacturing of oral solid dosage forms. Int J Pharm. 2020;579:119194. doi:10.1016/j.ijpharm.2020.119194.
3. Wahlich J. Review: Continuous manufacturing of small molecule solid oral dosage forms. Pharmaceutics. 2021;13(8):1311. doi:10.3390/pharmaceutics13081311.
4. U.S. Food and Drug Administration. PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance: Guidance for Industry. Rockville, MD: FDA; 2004.
5. Fonteyne M, Vercruysse J, De Leersnyder F, Van Snick B, Vervaet C, Remon JP, et al. Process analytical technology for continuous manufacturing of solid-dosage forms. TrAC Trends Anal Chem. 2015;67:159-166. doi:10.1016/j.trac.2015.01.011.
6. Simon LL, Pataki H, Marosi G, Meemken F, Hungerbühler K, Baiker A, et al. Assessment of recent process analytical technology (PAT) trends: a multiauthor review. Org Process Res Dev. 2015;19(1):3-62. doi:10.1021/op500261y.
7. Domokos A, Nagy B, Szilágyi B, Marosi G, Nagy ZK. Integrated continuous pharmaceutical technologies—a review. Org Process Res Dev. 2021;25(4):721-739. doi:10.1021/acs.oprd.0c00504.
8. Nagy B, Galata DL, Farkas A, Nagy ZK. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing—a review. AAPS J. 2022;24(4):74. doi:10.1208/s12248-022-00706-0.
9. Rezaeizadeh M, Razavi SM, Muzzio FJ. Current state of machine learning implementation in pharmaceutical process modeling for oral solid dosage forms. Int J Pharm. 2026;689:126479. doi:10.1016/j.ijpharm.2025.126479.
10. Roggo Y, Chalus P, Maurer L, Lema-Martinez C, Edmond A, Jent N. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. J Pharm Biomed Anal. 2007;44(3):683-700. doi:10.1016/j.jpba.2007.03.023.
11. De Beer T, Burggraeve A, Fonteyne M, Saerens L, Remon JP, Vervaet C. Near infrared and Raman spectroscopy for the in-process monitoring of pharmaceutical production processes. Int J Pharm. 2011;417(1-2):32-47. doi:10.1016/j.ijpharm.2010.12.012.
12. Blanco M, Villarroya I. NIR spectroscopy: a rapid-response analytical tool. TrAC Trends Anal Chem. 2002;21(4):240-250.
13. Kourti T, MacGregor JF. Process analysis, monitoring and diagnosis, using multivariate projection methods. Chemom Intell Lab Syst. 1995;28(1):3-21. doi:10.1016/0169-7439(95)80036-T.
14. Pestieau A, Krier F, Thoorens G, Dupont A, Chavez PF, Ziemons E, et al. Towards a real time release approach for manufacturing tablets using NIR spectroscopy. J Pharm Biomed Anal. 2014;98:60-67. doi:10.1016/j.jpba.2014.05.002.
15. Qin SJ. Process data analytics in the era of big data. AIChE J. 2014;60(9):3092-3100. doi:10.1002/aic.14523.
16. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future. Int J Pharm. 2021;602:120554. doi:10.1016/j.ijpharm.2021.120554.
17. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Woodcock J, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16:771-783.
18. Barenji RV, Akdag Y, Yet B, Oner L. Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0. Int J Pharm. 2019;567:118445. doi:10.1016/j.ijpharm.2019.06.036.
19. Kleinebudde P, Khinast J, Rantanen J, editors. Continuous Manufacturing of Pharmaceuticals. Hoboken, NJ: Wiley; 2017.
20. FDA. Development and Submission of Near Infrared Analytical Procedures: Guidance for Industry. Silver Spring, MD: U.S. Food and Drug Administration; 2020.
21. Van Snick B, Holman J, Cunningham C, De Beer T, Vervaet C, Remon JP, et al. Development of a continuous direct compression platform using a quality by design approach. Int J Pharm. 2017;528(1-2):576-584.
22. Nagy ZK, Galata DL, Farkas A, Nagy B. Machine learning applications in pharmaceutical manufacturing and PAT: opportunities and challenges. AAPS J. 2022;24:74.
23. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Artificial Intelligence in Drug Manufacturing. Discussion Paper. Silver Spring, MD: FDA; 2023.
24. International Council for Harmonisation. ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products. Geneva: ICH; 2023.
25. International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.
26. International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.
27. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. Geneva: ICH; 2023.
28. International Council for Harmonisation. ICH Q14: Analytical Procedure Development. Geneva: ICH; 2023.
29. International Society for Pharmaceutical Engineering. Pharma 4.0™ Baseline Guide. North Bethesda, MD: ISPE; 2023.

About The Author:

Devendra Ridhurkar, Ph.D., is the founder and CEO of RidNova Pharmaceuticals, a specialty pharmaceutical company that partners with pharmaceutical, biotech, and innovator companies globally, providing strategic technical expertise across product development. With nearly 20 years of experience, his expertise spans small molecules, complex generics, long-acting injectables, liposomes, solubility enhancements, modified-release products, biosimilars, biologics, and emerging applications of AI and PAT in pharmaceutical development and manufacturing. He previously held scientific and leadership roles at Adalvo, Neuraxpharm, Servier, and Dr. Reddy’s Laboratories. He received his Ph.D. in pharmaceutics and drug delivery systems from IIT-BHU, India.